Streetbeat News

TVGN

Tevogen Bio Holdings Inc.

Industry

Biotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Open

1.50

Mkt cap

249M

Volume

1.3M

High

1.57

P/E Ratio

24.33

52-wk high

21.09

Low

1.37

Div yield

N/A

52-wk low

0.26

LENZ Therapeutics shares rose 18% in pre-market trading following positive Phase 3 trial results in China. Other notable pre-market movers include Healthcare Triangle, Pixie Dust Technologies, and Jet.AI, with significant gains, while SMX and Upexi saw declines.

Portfolio Pulse from Avi Kapoor

October 28, 2024 | 10:32 am

Several major stocks, including Capri Holdings, Coursera, and DexCom, experienced significant declines in pre-market trading. Capri's shares plummeted after a judge blocked its merger with Tapestry, while Coursera and DexCom fell due to disappointing financial guidance and results.

Portfolio Pulse from Avi Kapoor

October 25, 2024 | 1:14 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

In Thursday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares surged after announcing its AI division, Tevogen AI, joined Microsoft's startup program. This partnership aims to leverage Microsoft's AI technology to reduce drug development costs and expedite drug discovery. Tevogen's stock rose 60.3% following the news.

Portfolio Pulse from Dylan Berman

October 23, 2024 | 4:41 pm

Several health care stocks experienced significant price movements during Wednesday's intraday session. CNS Pharma, Virax Biolabs Group, and Tevogen Bio Holdings were among the top gainers, while Alto Neuroscience and Silexion Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:31 pm

Tevogen Bio's stock is rising following the announcement that its AI initiative, Tevogen AI, has joined Microsoft for Startups.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:46 pm

Tevogen Bio's AI initiative, Tevogen AI, has joined the Microsoft for Startups program, which could enhance its technological capabilities and market reach.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:39 pm

Tevogen Bio is set to announce timelines for revenue forecast updates and operational readiness, expecting $1 billion in revenue during the launch years for oncology and specialty care. The 5-year revenue estimate is between $28 billion and $36 billion. Updates on Tevogen AI and manufacturing progress will also be provided.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 6:35 pm

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) has announced a revenue forecast for its specialty care pipeline, projecting nearly $1 billion in its launch year and a cumulative $18-$22 billion over five years. This includes treatments for SARS-CoV-2 and various cancers.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 8:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.